将恒河猴巨细胞病毒/猴免疫缺陷病毒疫苗与一种中和抗体联合使用，以保护恒河猴免受猴免疫缺陷病毒攻击。
Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.
作者信息
Coppola Jessica, Parren Mara, Bastidas Raiza, Saye Karen, Malvin Jacqueline, Jardine Joseph G, Gilbride Roxanne M, Ojha Sohita, Feltham Shana, Morrow David, Barber-Axthelm Aaron, Bochart Rachele, Fast Randy, Oswald Kelli, Shoemaker Rebecca, Lifson Jeffrey D, Picker Louis J, Burton Dennis R, Hansen Scott G
机构信息
Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
出版信息
Front Microbiol. 2025 Jun 2;16:1592647. doi: 10.3389/fmicb.2025.1592647. eCollection 2025.
A vaccine is considered essential for controlling the HIV pandemic and ultimately eradicating AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have shown the ability to protect against the simian counterpart of HIV, SIV, in rhesus macaques. In this study, we provide preliminary evidence that combining these orthogonal antiviral mechanisms can offer increased protection against SIV. Specifically, the replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced by the presence of a passively administered neutralizing antibody at incompletely protective levels. This report encourages studies involving larger cohorts of macaques and alternative methods for administering neutralizing antibodies.
疫苗被认为是控制艾滋病毒大流行并最终根除艾滋病的关键。在恒河猴中，中和抗体和MHC-E限制的CD8 + T细胞已显示出对艾滋病毒的猿类对应物——猴免疫缺陷病毒（SIV）的保护能力。在本研究中，我们提供了初步证据，表明将这些正交抗病毒机制结合起来可以增强对SIV的保护。具体而言，在接种基于恒河猴巨细胞病毒（RhCMV/SIV）的疫苗后观察到的复制停滞，因存在不完全保护性水平的被动给予的中和抗体而增强。本报告鼓励开展涉及更大恒河猴群体以及中和抗体给药替代方法的研究。
Zotero 插件